Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 4Phase NA 2Phase 3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 45Genitourinary 14Thoracic 4Other hematologic neoplasm 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Head & Neck 1Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Sorafenib × Tumor-Agnostic × Clear all
NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
543 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT00625378 2022-09-01

STEP

Bayer

Phase 3 Completed
206 enrolled 17 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡